Fig. 1. Effects of theracurmin on hepatic lipid accumulation in mice fed with HFD. (A) Liver sections were stained with H&E or oil-Red O staining. The mice were fed either a ND or HFD for 12 weeks. theracurmin (500, 1,000, and 2,000mg/kg) or silymarin (25mg/kg) (reference control) was administered to the mice at the same time. H&E staining. The livers of the mice were stained with H&E after a treatment with 500, 1,000, and 2,000mg/kg theracurmin for 12 weeks. CV, Central vein; PT, Portal triad area; Scale bars = 100 μm. Oil Red O staining. Each photo represents their groups after staining with Oil Red O in the liver. Scale bars = 100 μm. (B) Histomorphometric analysis. Measurement of hepatic steatosis region (%/mm2 of hepatic parenchyma) and diameter of hepatocyte (mm/hepatocyte). Data were expressed as mean ± SEM statistically analyzed by LSD-test methods. Significant versus normal control, ##p< 0.01; significant versus HFD-fed group, **p< 0.01 (n = 10). G1: ND (normal saline), n = 10; G2: HFD + vehicle (normal saline), n = 10; G3: HFD + theracurmin (500 mg/kg/day), n = 10; G4: HFD + theracurmin (1,000 mg/kg/day), n = 10; G5: HFD + theracurmin (2,000 mg/kg/day), n = 10; G6: HFD + reference control (silymarin 25 mg/kg/day), n = 10.
© ToxicolRes
